Immuneering Corp - Ordinary Shares Class A

NASDAQ:IMRX  
12.03
-0.45 (-3.61%)
Products, Mergers / Acquisitions

Immuneering Says On Dec 22 Entered Into A Share Purchase Agreement With Bioarkive, Inc

Published: 12/22/2021 18:58 GMT
Immuneering Corp - Ordinary Shares Class A (IMRX) - Immuneering - on Dec 22 Entered Into a Share Purchase Agreement With Bioarkive, Inc.immuneering - Due to Deal Under Spa, Acquired All of Equity of Bioarkive, Which Accordingly Then Became a Wholly Owned Subsidiary of Co.
Immuneering Corp - Purchased on Closing Date All Outstanding Shares of Capital Stock of Bioarkive for Purchase Price of $8.75 Million.
Immuneering - Co's Dual Mitogen-activated Protein Kinase Kinase, Product Candidate, Imm-1-104, is Currently Undergoing Ind Enabling Studies.
Immuneering Corp - Now Plans to Submit an Ind for Imm-1-104 to FDA in Q3 of 2022.
Further Company Coverage: Imrxo ((reuters.
Briefs@thomsonreuters.
Com;)).